Table 4

Relative risks of progression within 24 months and overall death within 5 years according to clinicopathological factors and RBM3 expression in patients with Ta and T1 tumours
Risk of progression within 24 months Risk of death within 5 years
Univariable Multivariable Univariable Multivariable
n(events) HR(95%CI) HR(95%CI) n(events) HR(95%CI) HR(95%CI)
Age
Continuous 134(19) 1.02(0.98-1.07) 1.01(0.97-1.06) 231(88) 1.06(1.04-1.09) 1.06(1.04-1.08)
Gender
Female 29(2) 1.00 1.00 43(12) 1.00 1.00
Male 105(17) 2.48(0.57-10.74) 1.98(0.45-8.64) 188(76) 0.62(0.34-1.13) 1.67(0.90-3.10)
Grade
Low 48(3) 1.00 1.00 81(19) 1.00 1.00
High 86(16) 3.24(0.94-11.12) 3.32(0.97-11.40) 150(69) 2.22(1.33-3.68) 1.31(0.73-2.35)
Stage
Ta 68(7) 1.00 1.00 115(35) 1.00 1.00
T1 66(12) 1.90(0.75-4.83) 1.24(0.44-3.46) 116(53) 0.61(0.40-0.93) 1.61(1.04-2.49)
RBM3 expression*       RBM3 expression*      
High 31(1) 1.00 1.00 Positive 198(69) 1.00 1.00
Negative/Intermediate 103(18) 5.92(0.79-44.39) 6.10(0.81-45.69) Negative 33(19) 2.00(1.21-3.33) 1.64(0.96-2.78)

For PFS a dichotomised variable comparing patients with negative or intermediate RBM3 expression to those with high expression was applied. For 5 year OS, a dichotomised variable of negative versus any RBM3 expression was applied.

Boman et al.

Boman et al. BMC Urology 2013 13:17   doi:10.1186/1471-2490-13-17

Open Data